Cls Pharmaceuticals, Inc.

Clarus Cls Holdings, LLC

Merck Sharp + Dohme Corp.

Schering Corporation

Pharmacopeia Drug Discovery, Inc.

Schering-plough Corporation

Scheeing Corporation

Foresight Biotherapeutics

Pharmacopeia Inc.

Bo Liang

Joseph A Capriotti

C Michael Samson

Robert G Aslanian

Kevin D McCormick

Christopher W Boyce

Pietro Mangiaracina

Chia-Yu Huang

Neng-Yang Shih

Younong Yu

Manuel De Lera Ruiz

Rong-qiang Liu

Junying Zheng

Salem Fevrier

Ruiyan Liu

Lisa Guise-Zawacki

Michael Berlin

Purakkattle J Biju

Huagang Lu

Michael Weiser

Stephanie Louise Ciesla

Jason Stein

Michael C Samson

Joseph Capriotti

Pietro Mangiarcina

A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.

Methods of using ophthalmic compositions comprising povidone-iodine

Ophthalmic compositions comprising povidone-iodine

In its many embodiments, the present invention provides a novel class of biaryl compounds as inhibitors of &#xff;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#xff;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Functionally selective alpha2C adrenoreceptor agonists

In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as &#x3b1;2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the &#x3b1;2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.

ALPHA2C adrenoreceptor agonists

In its many embodiments, the present invention provides a novel class of indolines as inhibitors of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

&#x3b1;2C adrenoreceptor agonists

Growing community of inventors

East Brunswick, NJ, United States of America

Bo Liang